Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab.
Fabbi M, Costa D, Russo D, Arenare L, Gaggero G, Signoriello S, Scambia G, Pisano C, Colombo N, Losito NS, Filaci G, Spina A, Califano D, Scognamiglio G, Gadducci A, Mezzanzanica D, Bagnoli M, Ferrini S, Canzonieri V, Chiodini P, Perrone F, Pignata S.
Fabbi M, et al. Among authors: costa d.
Diagnostics (Basel). 2022 Aug 31;12(9):2118. doi: 10.3390/diagnostics12092118.
Diagnostics (Basel). 2022.
PMID: 36140519
Free PMC article.